Knee Osteoarthritis
Conditions
Keywords
bone marrow aspirate concentrate, minimally manipulated adipose tissue, BMAC, MM-AT, intra-articular injection, knee injection, mesenchymal stromal cells, Randomized controlled trial, cellular orthobiological products
Brief summary
The MAST-GR study is a randomized controlled interventional trial with parallel treatment arms and 1:1 allocation The primary objective of the study is to compare the safety and efficacy of a single intra-articular infiltration of Bone marrow aspirate concentrate (BMAC) with one of minimally manipulated adipose tissue (MM-AT) so as to determine the most effective cellular product in treating patients with knee osteoarthritis (OA). The secondary objective is to demonstrate whether intra-articular infiltration of BMAC or MM-AT can induce disease-modifying effects in knee OA by imaging and biological assessments on peripheral blood. The tertiary objective of the study is to identify factors that influence the clinical response to treatment (baseline characteristics of patients, biological characteristics of the treated knee, characteristics of cellular products, BMAC and MM-AT).
Detailed description
Patients with symptomatic unilateral knee OA will be included in a randomized controlled Trial (RCT), in which one group of patients will be treated with 1 intra-articular infiltration of BMAC, and one group will be treated with 1 intra-articular infiltration of MM-AT. A total of 204 patients will be included and will undergo infiltrative treatment after collecting informed consent for study participation and master data. Patients will be clinically evaluated at 0-2-6-12 months follow-up. Possible disease-modifying effects of the two cell products will be investigated by analysis on peripheral blood at 0-2-6-12 months follow-up and by evaluation of radiographic and magnetic resonance imaging (MRI) at 0 and 12 months follow-up. In addition, characterization of the portion of BMAC and MM-AT remaining from treatment will be carried out, as well as baseline assessment of peripheral blood on all patients, and synovial fluid and synovial membrane, where possible, to analyze their influence on clinical outcome.
Interventions
single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
BIOLOGICALintra-articular injection of Minimally manipulated adipose tissue
single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
Sponsors
Istituto Ortopedico Rizzoli
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
To ensure the blinding of the health care personnel who will perform the checks (single-blind), follow-up visits will be performed by physicians not involved in the treatment procedures.
Intervention model description
This is a randomized trial with 1:1 allocation.
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients with symptomatic unilateral knee OA with: 1. Men or women aged 40 to 75 years; 2. Signs and symptoms of OA with a clinical history of gonalgia or swelling for at least 6 months; 3. Radiographic signs of OA (Kellgren-Lawrence grade 1-4); 4. No benefit after at least 4 months of conservative treatment; 5. Ability and consent of patients to actively participate in clinical and radiological (rx and MRI) follow-up; 6. Signing of informed consent.
Exclusion criteria
1. Patients unable to express consent; 2. Patients aged \< to 40 and \> to 75 years; 3. Patients with axial deviations \> 5°; 4. Patients who have suffered trauma or undergone intra-articular infiltration of other substance in the previous 6 months; 5. Patients who have undergone knee surgery in the previous 12 months; 6. Patients with concomitant knee injuries causing joint pain or swelling (-focal full-thickness osteochondral defects, acute meniscal injuries); 7. Patients with malignant neoplasms; 8. Patients with uncompensated systemic diseases (rheumatic diseases, metabolic disorders such as diabetes and thyroid diseases); 9. Patients with infectious diseases; 10. Patients with histories of alcohol or drug abuse; 11. Patients who are pregnant; 12. Patients with allergies to anesthetics used in the procedure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Western Ontario and McMaster University Osteoarthritis index (WOMAC) - Pain subscale | 6 months follow-up | It is a pathology-specific questionnaire used for the assessment of referred pain at the knee joint level in patients with OA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | baseline, 2 months, 6 months, 12 months follow-up | It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient. It measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome |
| Knee Injury and Osteoarthritis Outcome Score (KOOS) | baseline, 2 months, 6 months, 12 months follow-up | This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines the following categories: symptoms, stiffness, pain, daily activities, sports and quality of life |
| Visual Analogue Scale (VAS) | baseline, 2 months, 6 months, 12 months follow-up | Visual analog scale consisting of a straight line segment (10 cm length), the ends of which correspond to "no pain" (0) and "the strongest pain imaginable" (10). |
| EuroQol Visual Analogue Scale (EQ-VAS) | baseline, 2 months, 6 months, 12 months follow-up | EQ-VAS is a visual analog scale that has a range of scores from 0 (worst imaginable health condition) to 100 (best imaginable health condition). |
| Tegner Activity Level Scale | baseline, 2 months, 6 months, 12 months follow-up | Tegner Activity Level Scale is a questionnaire to find out the patient's level of physical activity.All patients will indicate the type of sporting activity performed and its frequency. |
| Objective parameters- Range of Motion | baseline, 2 months, 6 months, 12 months follow-up | Evaluation of the Range of Motion for comparative analysis. |
| Objective parameters - Circumferences | baseline, 2 months, 6 months, 12 months follow-up | Bilateral trans- and supra- patellar circumferences measurement for comparative analysis |
| Patient Acceptable Symptom State (PASS) | baseline, 2 months, 6 months, 12 months follow-up | A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering "yes" or "no. |
| Minimally Clinical Important Difference (MCID) | baseline, 2 months, 6 months, 12 months follow-up | The patient should indicate the degree of perceived improvement after the infiltrative procedure. |
| Expectations about the effectiveness of the treatment | baseline | The patient should indicate at baseline what clinical benefits he or she expects from the treatment according to the question, "What benefits do you expect to get as a result of the treatment you will undergo?" the patient can choose from one of the following items:Full recovery, Definitely better, Much better, Slightly better,No change |
| Kellgren-Lawrence score | baseline, 12 months follow-up | The Kellgren Lawrence scale classifies knee OA into 4 grades of subsequent greater severity, the parameters used being reduced joint space and the presence of osteophytes |
| 3 Tesla Nuclear Magnetic Resonance Imaging (3T MRI) | baseline, 12 months follow-up | Sequences such as T2-weighted FSE, FS-3D SPGR, and T2 Mapping will be used to assess cartilage thickness and signal, the presence of cysts and subchondral edema, joint profile, the presence of osteophytes and their size, the status of the menisci, both medial and lateral, and the status of the synovium. |
| Analysis of circulating micro RNAs | baseline, 2 months, 6 months, 12 months follow-up | miRNAs, involved in OA progression, will be identified and quantified, including miR675-5p, miR-31-5p and miR-33a-5p |
Countries
Italy
Contacts
CONTACTLuca Andriolo, MD
CONTACTRoberta Licciardi, MSc
PRINCIPAL_INVESTIGATORLuca Andriolo, MD
Istituto Ortopedico Rizzoli - II Clinica Ortopedica e Traumatologica
Outcome results
None listed